Publications by authors named "Li-Ran Ye"
The function and survival of melanocytes is regulated by an elaborate network of paracrine factors synthesized mainly by epidermal keratinocytes (KCs). KCs and melanocytes respond to UV exposure by eliciting a tanning response. However, how KCs and melanocytes interact in the absence of UV exposure is unknown.
View Article and Find Full Text PDFArticle Synopsis
- Patients with psoriasis may see worsened symptoms after a COVID-19 infection, and this study aimed to explore this issue in those on three biologics: adalimumab, secukinumab, and ixekizumab.
- A prospective study with 209 patients showed that while psoriasis severity can worsen after COVID-19, those treated with biologics had a lower chance of exacerbation, particularly those on ixekizumab, with statistically significant results.
- The findings suggest that continuing biologic treatment during COVID-19 may offer protective benefits for psoriatic patients, highlighting the importance of maintaining therapy amid infection risks.*
The skin is the outermost barrier that separates the human body from the external environment. In psoriasis, immune cells reside within or infiltrate the epidermis to form the epidermal (epithelial) immunological microenvironment (EIME) and engage in complex interactions with keratinocytes, nerves, and microbiota. The proposed hypothesis is that psoriasis is a chronic inflammatory disease mainly mediated by a specific inflammatory environment composed of keratinocyte-neuro-immune cell units (KNICUs).
View Article and Find Full Text PDFSecukinumab is a recombinant, fully human monoclonal anti-IL-17A antibody approved to treat moderate-to-severe psoriasis and psoriatic arthritis. Its effectiveness and safety have been confirmed, but a gradual increase in the secukinumab dosing interval has not been investigated. To assess the feasibility, efficacy, and safety of gradually increasing the secukinumab dosing interval; the interval duration was determined by changes in the Psoriasis Area and Severity Index scores.
View Article and Find Full Text PDFArticle Synopsis
- Treatment for pediatric psoriasis is difficult due to limited real-world evidence, particularly for biologic therapies.
- A study evaluated the effectiveness and safety of three biologics (adalimumab, secukinumab, ixekizumab) in children under 18 with psoriasis by tracking 38 patients over 52 weeks.
- Results showed that all patients improved significantly within 12 weeks with minimal side effects, confirming the efficacy and safety of these treatments for pediatric psoriasis.*
Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction.
Front Med (Lausanne)
October 2021
Psoriasis is a chronic multisystem inflammatory disease that affects ~0.1-1.5% of the world population.
View Article and Find Full Text PDF